Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

IPA Best of Health Awards

- PMLiVE

Janssen submits blood cancer drug in EU

Seeks EMA approval for ibrutinib

- PMLiVE

Interview: Harvey Berger and Timothy Clackson, Ariad

Ariad’s CEO and president of R&D talk about following their own path in oncology

- PMLiVE

Gilead halts leukaemia study on positive results

Idelalisib provides significant benefit in chronic lymphocytic leukaemia

- PMLiVE

Ariad gets EU green light for leukaemia drug Iclusig

EC approves drug in two forms of the blood cancer

- PMLiVE

Langland and McCann big winners at 2013 IPA Best of Health Awards

Langland and McCann Health China both receive ‘Best of Show’ honours at awards to recognise creativity in healthcare adveritsing

- PMLiVE

Leukaemia drug prices “unsustainable” say cancer experts

Study says patients may not be able to afford effective treatment

- PMLiVE

EU recommendations for Gilead, Ariad and Baxter drugs

EMA backs use of HyQvia, Iclusig and Stribild

- PMLiVE

Pfizer gets CHMP backing for leukaemia drug bosutinib

Provides option for patients resistant to tyrosine kinase inhibitors

- PMLiVE

Early FDA approval for Ariad’s leukaemia drug Iclusig

Available in US three months ahead of schedule

- PMLiVE

Boehringer takes leukaemia drug volasertib into phase III

Shows positive results in a difficult-to-treat patient population

- PMLiVE

FDA approves Teva’s leukaemia drug Synribo

Accelerated approval means early competition for Pfizer’s Bosulif

European approvals for J&J cancer treatments

EC passes new Dacogen indications and backs subcutaneous Velcade

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links